Compare Heron Therapeutics Inc (HRTX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Realty Income Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Realty Income Corp trades at $54.22 (market cap $50.48B). The key difference: Realty Income Corp is far larger — about 681.8× Heron Therapeutics Inc's market cap, and Realty Income Corp pays a 6.11% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Realty Income Corp for 127 Days on average.
| HRTX | O | |
|---|---|---|
Market Cap | $74.04M | $50.48B |
Volume | 3,668,095 | 6,493,749 |
Sector | Health | Real Estate |
52-Week High | $1.49 | $67.56 |
52-Week Low | $0.27 | $53.35 |
Typical Hold Time | 35 Days | 127 Days |
Enterprise Value | $180.78M | $81.11B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Realty Income (O) trades at $54.17, down 0.15% with a bearish technical signal. The stock faces pressure from rising Treasury yields but maintains strong fundamentals including 92.56% gross margins and consistent dividend payments. Recent earnings have missed expectations, though revenue growth continues with 2025 reaching $5.75B. Analyst consensus remains positive with a $64.80 price target despite technical weakness.
The stock offers income potential with its 6%+ dividend yield and 136 consecutive dividend increases, but faces headwinds from interest rate sensitivity and recent earnings misses. Long-term fundamentals remain solid with A-rated credit and near-99% occupancy, though near-term technical pressure suggests cautious entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
